Advanced Search

Submit Manuscript

ADVANCE ONLINE PUBLICATION

RESEARCH HIGHLIGHTS

Immune checkpoint inhibitors as senolytic agents

Parminder Singh1 , Pankaj Kapahi1 , Jan M. van Deursen2,*

1Buck Institute for Research on Aging, Novato, CA, USA
2Cavalry Biosciences, Novato and San Francisco, CA, USA
* Correspondence: Jan M. van Deursen(janvandeursen2@gmail.com)

Senolysis, the elimination of senescent cells (SNCs), is a novel therapeutic concept for the treatment of aging and age-related diseases that has scored a first success in the clinic for the treatment of diabetic macular edema with UBX1325. In a recent Nature paper, Wang et al. now report that subsets of SNCs express PD-L1 and describe a novel mode of senolysis through clearance of these cells by immune checkpoint inhibitors.

https://doi.org/10.1038/s41422-022-00761-4

FULL TEXT | PDF

Browse 353